Answers are grounded in this paper and cite their sources.
The global emergence of antimicrobial resistance is driving the development of novel strategies for treating bacterial infections. In this context, dextran-based single-chain polymeric nanoparticles (DXT-SCPNs) have been developed as antibiotic delivery systems for the treatment of pulmonary infections. A series of DXT-SCPNs were formulated with apramycin with different physicochemical properties, namely three degrees of substitution (with a low degree of crosslinking in all cases): low (L-DS a ), medium (M-DS a ), or high (H-DS a ), and two degrees of crosslinking (with a medium degree of substitution in both nanoparticles): low (M-DSa) or high (H-CL a ). Their in vitro activity against eleven Acinetobacter baumannii clinical isolates was assessed compared to the free drug, using minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC) and time-kill kinetic (TKK) assays. Overall, no statistically significant differences were observed between the antimicrobial activity of free and formulated apramycin. Nevertheless, a slight trend towards higher activity was observed in the cases of M-DS a and H-CL a .
No takes yet. Share an insight, caveat, or question.
Ramos et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: